Disease-modifying anti-nephropathic drugs (DMANDs) – A definition proposed by the IWG of ERA
What does the Cardiovascular-Kidney-Metabolic (CKM) Syndrome mean for nephrologists?
EuReCa-M Working Group
Speaker
Patrick Mark, United Kingdom
Panellists
Shanmugakumar Chinappa, United Kingdom
Evangelia Ntounousi, Greece
Moderator
Francesca Mallamaci, Italy